|Last Price||Today's Change||52-Week Range||Trading Volume|
|93.85||0.58 (+0.62%)||66.85 - 96.44||6.1 million (Above Avg)|
Market data as of 3:59PM 09/19/14. Quotes are delayed by at least 15 min.
Phase III FIRST™ (MM-020/IFM 07-01) Trial of REVLIMID® (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine
09/04/2014 7:30 AM ET